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ABSTRACT
Rituximab 375 mg/m2 weekly for four weeks has significant activity in patients with immune thrombocytopenia. We evaluated the activ-
ity of  lower dose rituximab (100 mg iv weekly for 4 weeks) in 28 adults with idiopathic thrombocytopenic purpura. Overall (platelet count
> 503109/L) and complete responses (platelet count > 1003109/L) were achieved in 21/28 (75%) and 12/28 (43%) patients respec-
tively. The median time to response and time to complete response were 31 and 44 days respectively. After a median follow-up of 11
months (range 3-18), 7/21 (33%) patients relapsed and 3 needed further treatments. In patients with idiopathic thrombocytopenic pur-
pura, lower dose rituximab seems to show similar activity to standard dose.
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Introduction
Rituximab is an emerging new agent for the treatment of
several autoimmune disorders1-9 and, in particular, many
reports highlighted the effect of rituximab in idiopathic
thrombocytopenic purpura (ITP).10-18 To date, rituximab has
been administered with the same schedule proposed for B-
cell lymphomas, i.e. 375 mg/m2 every seven days for four
weeks. Very few dose-finding and pharmacokinetic studies
have been performed in autoimmune diseases.19 In this con-
text, the B-cell total mass is much less than in patients with
lymphoma and, therefore, a reduced dosage of rituximab
might still be sufficient for its therapeutic purpose. Based on
this assumption, we performed a prospective clinical trial
using lower dose rituximab in patients with ITP. We explored
response rates of lower dose rituximab and correlated results
with biological findings.
Design and Methods
Patients
From February 2006 to April 2007, 28 consecutive adult
patients (median age 43 years, range 16-71 years) with ITP
that had relapsed or were refractory at least to a full course
of steroid therapy were included in this prospective, multi-
center, phase II study, approved by the ethical boards of the
co-ordinating center. Patients’ inclusion criteria were: a diag-
nosis of ITP according to the guidelines of the American
Society of Hematology,20 active symptomatic disease or in
need of chronic treatment with steroids to maintain a safe
number platelet count (≥20×109/L), previous treatment with
at least one line of therapy, written informed consent.
Exclusion criteria were: HIV, HCV serology or HBsAg posi-
tivity, positive pregnancy test, malignant diseases. A previ-
ous effective treatment with standard dose rituximab was
not considered an exclusion criterion. 
Patients’ main characteristics are summarized in Table 1.
The relatively high median platelet count at baseline
(31×109/L, range 6-114×109/L) reflected the concomitant
administration of steroids in a large number of cases (21/28
patients) when rituximab was started. Therefore, all
patients included in this study were representative of a pop-
ulation of symptomatic ITP requiring treatment.
Treatment
Rituximab was given at the fixed dose of 100 mg admin-
istered as an intravenous (iv) infusion weekly (on day 1 of
weeks 1, 2, 3 and 4). The choice to use this fixed dose was
rather empirical and also based on administration conven-
ience. Patients received oral acetaminophen 500 mg and iv
chlorphenamine 10 mg as pre-medication therapy. No other
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cytotoxic or immunosuppressive drugs were given in
association with rituximab. Patients with steroid
dependency to maintain a low platelet count
>20×109/L or active bleeding before rituximab admin-
istration were allowed to continue steroids also during
rituximab therapy at the individual minimal effective
dosage sufficient to maintain a safe number of
platelets. Nevertheless only patients that reached
steroid discontinuation during or soon after rituximab
were considered for response. 
Response criteria 
The evaluation of the response was made monitoring
the platelet count every week during the first month of
treatment, then at bi-weekly intervals up to the sixth
month and then monthly. A complete response (CR)
was defined as a platelet count >1003109/L and discon-
tinuation of the steroid therapy. This level of platelets
was chosen in accordance with our previous reports.9,14,16
However, we also evaluated the rate of patients who
achieved a complete normalization of platelet count (i.e.
>1503109/L). Partial response (PR) was defined as a
platelet level between 50 and 1003109/L and discontin-
uation of the steroid therapy. An overall response (OR)
was defined as a partial or complete response. Patients
with less than PR were considered non-responders
(NR). Patients who required steroid administration dur-
ing rituximab therapy were considered responders only
if a steroid discontinuation (previously not possible)
was achieved. The hematologic improvement was also
assessed evaluating the time to response (TTR; i.e. the
time necessary to reach a platelet count ≥503109/L) and
the time to complete response (TCR; i.e. the time nec-
essary to reach CR). For relapse free survival (RFS) we
considered the whole period of spontaneous mainte-
nance of the best response achieved (i.e. CR or PR). For
treatment free survival (TFS) we considered the period
between response to rituximab and the need for further
therapy because of symptomatic or severe (<203109/L)
thrombocytopenia. Therefore, those patients who, dur-
ing the period of observation after rituximab, lost their
best response but did not require further treatment were
not considered as failure. Rituximab-related toxicity
was assessed during the period of treatment and during
the follow-up. Clinical and laboratory side effects were
evaluated and graded according to the WHO scale.
B-cell depletion assessment
In order to evaluate B-cell depletion after rituximab,
peripheral blood immunophenotypic analyses of CD19-
CD20 lymphoid markers were performed in 21 avail-
able patients at baseline and then monthly from the
beginning of treatment.
Blood sampling and pharmacokinetic analysis
Blood sampling for rituximab determination was per-
formed at weeks +4, +8, +10 and +12 after the start of
the therapy in a total of 8 patients. Samples from all
time points were stored at –20°C until analysis. Ritu-
ximab concentration-time data were analyzed using a
statistical pharmacokinetic population software (P-
Pharm, version 3, Simed, Creteil, France). In all cases,
rituximab plasma concentration was determined using a
previously validated enzyme-linked immunoassay
(ELISA.21
Statistical analysis
Stepwise logistic regression was used to assess
whether response to low dose rituximab in patients
with ITP was associated with age, gender, diagnosis-
rituximab interval and baseline CD20+ lymphocytes.
Results were considered statistically significant when
p ≤ 0.05. Graphs of RFS and TFS were achieved using
the Kaplan-Meier method. Statistical analyses were
performed in Stata/SE 9.0 for Windows.
Results and Discussion
All 28 patients included in the study completed the
therapeutic program receiving the four infusions of rit-
uximab as scheduled. Overall, CR and PR rates were
21/28 (75%), 12/28 (43%), 9/28 (32%) respectively
(Table 2). Ten out of 28 patients (35%) achieved a com-
plete normalization of platelet count (i.e. > 1503109/L).
The 2 patients previously treated with standard dose
rituximab again achieved the same type of response: 1
CR still lasting after nine months of follow-up and 1
PR lasted four months but with up till now no need of
further treatments (17 months follow-up). The TTR to
rituximab standard and low dose rituximab of these 2
patients was similar (7 and 60 days). Stepwise logistic
regression showed that both CR and OR were associ-
ated with age. CR showed an odds ratio=0.94, CI 95%
[0.90; 0.99] and OR an odds ratio=0.93, CI 95% [0.86;
0.99], showing that as age increases the complete or
overall response probability decreases. TTR was
observed within day +7 in 5 out of 16 evaluable
responding patients (31%) and in all remaining cases
after day 22, with a median time of 31 days. Median
TCR was 44 days (range 7-90). The median time of
observation, in responding patients, was 11 months
Table 1. Main clinical and laboratory features of patients before rit-
uximab treatment.
Patients 28
Median age, years (range) 43 (16-71)
Males/females 19/9
Median weight, kg (range) 72 (42-112)
Median surface area, m2 (range) 2  (1.4-2.3)
Diagnosis-rituximab median interval, months (range) 26 (1-451)
Median platelet count 31 (6-114)
before rituximab, x109/L (range)
Previous treatments
Steroids 28
High dose IVIG 9
Azathioprine 3
Danazole 2
Standard dose rituximab 2
Vincristine and cyclophosphamide 1
Splenectomy 1
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(range 3-18). Seven out of 21 responding patients
(33%) relapsed [3/12 CR after two (n=1), and three
months (n=2) and 4/9 PR after three, (n=1) and four
months (n=3)] relapsed and 3 needed further treat-
ments. Eleven month cumulative RFS and TFS proba-
bilities were 64% and 78% respectively (Figure 1). We
did not observe any infusion-related reactions. None
of the patients experienced opportunistic or other
severe infections and there was no evidence of signifi-
cant hematologic or non-hematologic toxicity. All
patients achieved complete B-cell depletion, with a
median B-lymphocyte count of 0.223109/L (range
0.04-0.96) at baseline, 0.003109/L (range 0.00-0.02) at
month 2 and 0.023109/L (range 0.00-0.07) at month 6.
The median plasma level of rituximab just after the last
infusion was 25.6 µg/mL (range: from 0 µg/mL to 77.9
µg/mL) (Table 2). Thereafter, rituximab concentrations
decreased following a decay characterized by a medi-
an elimination half-life of 536 hours (range: 377.5-665
hrs.) and detectable levels were reported till week 12
after the start of therapy in all but one patient. The
median plasma concentrations at 8, 10 and 12 weeks
after the start of therapy were 13 µg/mL (range: 0-29
µg/mL), 5 µg/mL (range: 0-24 µg/mL) and 4 µg/mL
(range: 0-12 µg/mL), respectively. 
This study shows that with lower dose rituximab
(approximately one seventh of the approved standard
dose in lymphoma) the level of B-cell depletion and
the response rates appear similar to those previously
observed with standard dosages in a population of ITP
patients with the same characteristics.14,16 Younger age
correlated with better response rate, while no relation-
ship could be found between response rate, gender,
diagnosis-rituximab interval and baseline CD20+ lym-
phocytes. Our experience confirms the results of
Provan and co-workers with the same 100 mg sched-
ule adopted for this study. In 11 patients with various
autoimmune pancytopenia the Authors reported activ-
ity in 4/7 patients with ITP, 1/1 with autoimmune pan-
cytopenia, 1/1 with autoimmune hemolytic anemia,
while no effect was observed in 1/1 patient with pure
red cell aplasia and in 1/1 with autoimmune neutrope-
nia.22 Data concerning the timing of response were
remarkably different to our previous experience14,16 and
with the results of other studies12,13 with standard dose.
It must be remarked, however, that some other groups
did not highlight this prompt response in the majority
of patients treated with standard dose.15,17 The fact that
we did not observe any infusion-related reaction
appears probably related both to the baseline lower B-
cell mass and to the lower dose of rituximab
employed. Rituximab pharmacokinetic data showed a
concentration time-course profile and a linear decay
that was similar, once corrected for the difference in
the dose, to that observed in previous studies with
standard dose in patients with lymphoma and autoim-
mune disorders.21 Our data show an elimination half-
life of 535.6 hours (range: 377.5-664.7 hours), which is
quite similar to that of 484.7 hours (range: 292.5-858.6
hours) previously found.21 Rituximab plasma levels
remained detectable for up to eight weeks following
completion of treatment. Furthermore, this data sug-
gest that anti-CD20 therapy for immune thrombocy-
topenia, as well as for other autoimmune diseases,
should be scheduled differently to that for lymphopro-
liferative disorders, possibly also with dramatic cost
improvement. Recently, Stasi and co-workers investi-
gated the effect of B-depletion after rituximab to revert
abnormalities of T-cell subsets in patients with ITP.23
An increased pre-treatment Th1/Th2 and Tc1/Tc2
ratios together with an increased expression of Fas lig-
and and Bcl-2 mRNA and a decreased expression of
Bax mRNA in Th cells, were inverted in responders
after treatment, whereas they remained unchanged in
non-responders. Our findings suggest that probably a
similar biological effect may be pursued also with low
dose rituximab. However, since all patients achieve B-
cell depletion but only some of them respond to ritux-
imab, it seems that other different pathogenic mecha-
nisms are involved in the development and the main-
tenance of ITP. In the future, the identification before
treatment of a patient’s specific pathway might help
optimize the therapy for this disease. In conclusion,
Table 2. Plasma concentrations of rituximab in groups with autoim-
mune disorders and ITP-low dose treated with weekly administra-
tions. Data are reported as medians (range).
Sampling time Rituximab plasma concentration (mg/mL)
Autoimmune disorders21 ITP-low dose
N. of patients 14 8
Rituximab dose 375 mg/m2 100 mg
Follow-up after the start of therapy (week)
4 194 (55.5-261) 26 (0-78)
5 137 (38-172.5)
6 86 (14-148)
7 63 (28-88)
8 41 (30-56) 13 (0-29)
9 25 (18-109)
10 5 (0-24)
12 4 (0-12)
Figure 1. Relapse free survival (RFS __) and treatment free survival
(TFS - - -) in 21 patients responding after rituximab treatment. 
0 5 10 15 20
Months
TFS
100%
75%
50%
RFS
Lower dose rituximab in ITP 
this study confirms the safety and the high potential
activity of rituximab in patients with ITP. Furthermore,
it highlights the importance for a more disease-specif-
ic therapeutic schedule and the need for randomized
studies. Lower dose rituximab led to response rates
similar to standard dose but with a slower timing of
response. 
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